Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Jacob Bornstein, Surita Roux, Lone Kjeld Petersen, Li Min Huang, Simon R. Dobson, Punnee Pitisuttithum, Javier Diez-Domingo, Andrea Schilling, Hany Ariffin, Richard Tytus, Richard Rupp, Shelly Senders, Eli Engel, Daron Ferris, Yae Jean Kim, Young Tae Kim, Zafer Kurugol, Oliver Bautista, Katrina M. Nolan, Sandhya SankaranarayananAlfred Saah, Alain Luxembourg

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


BACKGROUND AND OBJECTIVES: Human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9-14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) were noninferior to a 3-dose regimen (months 0, 2, 6) in young women (aged 16-26 years) 4 weeks after last vaccination in an international, randomized, open-label trial (NCT01984697). We assessed response durability through month 36. METHODS: Girls received 2 (months 0 and 6 [0, 6]: n = 301; months 0 and 12 [0, 12]: n = 151) or 3 doses (months 0,2, and 6 [0, 2, 6]: n = 301); boys received 2 doses ([0, 6]: n = 301; [0, 12]: n = 150); and young women received 3 doses ([0, 2, 6]: n = 314) of 9vHPV vaccine. Anti-HPV geometric mean titers (GMTs) were assessed by competitive Luminex immunoassay (cLIA) and immunoglobulin G-Luminex immunoassay (IgG-LIA) through month 36. RESULTS: Anti-HPV GMTs were highest 1 month after the last 9vHPV vaccine regimen dose, decreased sharply during the subsequent 12 months, and then decreased more slowly. GMTs 2 to 2.5 years after the last regimen dose in girls and boys given 2 doses were generally similar to or greater than GMTs in young women given 3 doses. Across HPV types, most boys and girls who received 2 doses (cLIA: 81%-100%; IgG-LIA: 91%-100%) and young women who received 3 doses (cLIA: 78%-98%; IgG-LIA: 91%-100%) remained seropositive 2 to 2.5 years after the last regimen dose. CONCLUSIONS: Antibody responses persisted through 2 to 2.5 years after the last dose of a 2-dose 9vHPV vaccine regimen in girls and boys. In girls and boys, antibody responses generated by 2 doses administered 6 to 12 months apart may be sufficient to induce high-level protective efficacy through at least 2 years after the second dose.

Original languageEnglish
Article numbere20194035
Issue number1
StatePublished - 1 Jan 2021

Bibliographical note

Publisher Copyright:
Copyright © 2021 by the American Academy of Pediatrics


Dive into the research topics of 'Three-year follow-up of 2-dose versus 3-dose HPV vaccine'. Together they form a unique fingerprint.

Cite this